The Innovative Molecular Analysis Technologies (IMAT) program was established to support the development, technical maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation. In support of its mission, the IMAT program utilizes a variety of investigator-initiated research project grant mechanisms while retaining a strong commitment to diversity and to the training of scientists and clinicians in cross-cutting, research-enabling disciplines.
The NCI is very pleased to announce that the IMAT program has approved reissuance for funding opportunity announcements through calendar year (CY) 2014.
Please use the link below for active funding opportunities, and next receipt dates.
Funding opportunities in technology development are intended to support the inception, maturation, and subsequent dissemination of technically innovative and potentially transformative emerging technologies. These opportunities exist in parallel with various educational and training programs aimed at the recruitment, retention, and promotion of a diverse pool of talent in areas of emerging technology.
IMAT support leads to new commercial glycan tagging kit from Cambridge Isotope Laboratories.
Congratulations to the Muddiman group (NCSU) for commercial launch of their INLIGHTTM glycan tagging kit, an important new tool for enabling mass spectrometry-based glycomics research. more +
New 2014 IMAT RFAs now open! The NCI commits $10.5M to IMAT RFAs in 2014! Next deadline Feb. 20, 2014.
The phase 1 and phase 2 solicitations for both innovative molecular/cellular analysis technologies and biospecimen science technologies have been reissued, with three receipt dates in 2014. Please see our Funding Overview page for links and more information. more +
Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)
The NCI has issued a new solicitation to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, or treatment of cancers in humans living in LMICs. more +
IMAT-SBIR PAR now posted.
The Innovative Molecular Analysis Technologies Development for Cancer Research and Clinical Care (IMAT-SBIR, PAR-13-327) funding opportunity provides to small businesses conducting research towards the commercial development of emerging molecular and/or cellular analytical technologies intended for cancer detection and/or characterization. more +
Fourteenth Principal Investigators Meeting
Innovative Molecular Analysis Technologies Program
Dates/location: November 21-22, 2013, Bethesda, MD
For more information about this event visit http://www.capconcorp.com/meeting/2013/IMAT/ more +
NCI's Clinical Proteomic Tumor Analysis Consortium
November 13, 2013
This free symposium highlights the work of investigators in the Clinical Proteomic Tumor Analysis Consortium (CPTAC). For more information about this event and CPTAC visit http://www.proteomics.cancer.gov. more +
IMAT-supported investigator named finalist for Innovation of the Year at the first annual SLAS meeting
Dr. David Beebe has been recognized at the first annual Society for Laboratory Automation & Screening (SLAS) meeting as a finalist for the Innovation of the Year Award for his breakthrough IFAST technology. more +
ThermoScientific to distribute IMAT-supported Iuvo™ technology in their Cellomics high-content analysis platform
The Iuvo™ platform is microchannel cell-based assay which will provide substantial enhancements to the Thermo Fisher Cellomics high-content analysis platform. more +